John Oyler Sells 25,054 Shares of BeiGene, Ltd. (BGNE) Stock

BeiGene, Ltd. (NASDAQ:BGNE) CEO John Oyler sold 25,054 shares of the stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $83.06, for a total transaction of $2,080,985.24. Following the completion of the transaction, the chief executive officer now owns 491,891 shares of the company’s stock, valued at approximately $40,856,466.46. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

John Oyler also recently made the following trade(s):

  • On Wednesday, November 15th, John Oyler sold 150,957 shares of BeiGene stock. The shares were sold at an average price of $80.50, for a total transaction of $12,152,038.50.

Shares of BeiGene, Ltd. (BGNE) traded up $4.26 during midday trading on Friday, reaching $84.69. 252,400 shares of the company’s stock were exchanged, compared to its average volume of 191,800. BeiGene, Ltd. has a 52 week low of $26.43 and a 52 week high of $118.95. The company has a debt-to-equity ratio of 0.57, a current ratio of 8.38 and a quick ratio of 8.38.

BeiGene (NASDAQ:BGNE) last posted its quarterly earnings data on Monday, November 13th. The company reported $2.54 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $2.31. The firm had revenue of $220.21 million for the quarter, compared to analysts’ expectations of $1.55 million. During the same period in the prior year, the company posted ($1.08) earnings per share. equities research analysts forecast that BeiGene, Ltd. will post -4.12 EPS for the current year.

TRADEMARK VIOLATION WARNING: This news story was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://sportsperspectives.com/2017/11/17/john-oyler-sells-25054-shares-of-beigene-ltd-bgne-stock.html.

Hedge funds have recently bought and sold shares of the business. Employees Retirement System of Texas purchased a new stake in BeiGene during the second quarter valued at about $2,855,000. Baillie Gifford & Co. lifted its stake in BeiGene by 5.0% during the second quarter. Baillie Gifford & Co. now owns 74,424 shares of the company’s stock valued at $3,349,000 after buying an additional 3,559 shares in the last quarter. Hillhouse Capital Management Ltd. lifted its stake in BeiGene by 172.6% during the second quarter. Hillhouse Capital Management Ltd. now owns 3,720,726 shares of the company’s stock valued at $167,433,000 after buying an additional 2,355,906 shares in the last quarter. Alliancebernstein L.P. purchased a new stake in BeiGene during the second quarter valued at about $7,373,000. Finally, Myriad Asset Management Ltd. lifted its stake in BeiGene by 16.6% during the second quarter. Myriad Asset Management Ltd. now owns 385,585 shares of the company’s stock valued at $17,351,000 after buying an additional 54,900 shares in the last quarter. 52.09% of the stock is owned by institutional investors.

A number of equities research analysts have weighed in on BGNE shares. Maxim Group set a $120.00 price target on shares of BeiGene and gave the company a “buy” rating in a report on Tuesday. Cowen and Company reissued a “buy” rating on shares of BeiGene in a report on Tuesday. Robert W. Baird reissued a “neutral” rating and issued a $83.00 price target (up from $58.00) on shares of BeiGene in a report on Tuesday. Zacks Investment Research downgraded shares of BeiGene from a “hold” rating to a “sell” rating in a report on Monday. Finally, Morgan Stanley reissued an “overweight” rating and issued a $95.00 price target (up from $87.00) on shares of BeiGene in a report on Friday, October 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. BeiGene presently has an average rating of “Buy” and a consensus price target of $96.67.

BeiGene Company Profile

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Insider Buying and Selling by Quarter for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply